United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction
|
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of
each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01 | Other Events |
As previously reported on Digital Health Acquisition Corp.’s (the “Company”) Current Reports on Form 8-K filed with the Securities and Exchange Commission on September 29, 2023 and October 13, 2023, on September 28, 2023 the Company received a letter from the staff (the “Staff”) of The Nasdaq Global Market (“Nasdaq Global”) that the Company’s securities (including the Common Stock, Units and Warrants) (the “Securities”) were subject to delisting from Nasdaq Global due to failure to regain compliance to certain Nasdaq Global listing requirement by the Staff’s required timeline (the “September 29, 2023 Letter”). On October 9, 2023, the Company received an additional letter from the Staff, which notified the Company that its not meeting the 400 total shareholders requirement under the Nasdaq Listing Rule 5450(a)(2) served as an additional ground for delisting the Company’s Securities from Nasdaq Global (the “October 9, 2023 Letter”).
In connection with the September 29, 2023 Letter, on October 4, 2023, the Company requested a hearing before the Nasdaq hearings panel (the “Hearing”) to appeal the MVLS determination and applied to list its Securities on The Nasdaq Capital Market (“NasdaqCM”). The Company also planned to address the deficiency outlined in the October 9, 2023 Letter at the Hearing. The Hearing was scheduled on November 30, 2023.
The Company’s application to transfer the listing of its Securities to NasdaqCM was granted on October 26, 2023. On November 1, 2023, the Company received a letter from the Nasdaq Global Hearings panel that due to the Company’s transfer of its listed Securities to NasdaqCM, the Hearing on November 30, 2023 regarding non-compliance with the Nasdaq Global listing standards has been cancelled. The Company’s Securities will continue to be listed and traded on The Nasdaq Stock Market on NasdaqCM.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DIGITAL HEALTH ACQUISITION CORP. | ||
| By: | /s/ Scott Wolf | |
| Name: | Scott Wolf | |
| Dated: November 6, 2023 | Title: | Chief Executive Officer and Chairman |